医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Panagene Succeeds in Developing ‘ctDNA Mutation Test’ KitLaunching a Total of 4 Breakthrough Commercial Products for Cancer Diagnostics

2014年09月16日 PM02:36
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

Panagene has been in focus on news of having developed a commercial ctDNA test kits that can detect mutated oncogene through blood test alone. This technology is based on PNA (Peptide Nucleic Acid) and it can detect various mutated oncogenes in real-time.

Panagene (President Sung Kee Kim), a Korea company specializing in molecular diagnostics, announced the successful development of the ‘C-melting technology’. Unlike traditional diagnostic products for invasive biopsy samples, this innovative ultra-sensitive test method makes it easy to effectively detect mutation from ctDNA in blood – as little as 0.01% of mutant ctDNA among excess of wild-type in blood can be detected in less than 3 hours.

The company explained “‘C-melting technology’ enabled this innovative, non-invasive, and easy method to accurately identify mutated oncogenes, unlike the ‘PNAClamp technology’, which is mainly used for invasive tissue biopsy”.

A total of four products were launched with this technology applied. These products are targeted to detect lung and colorectal cancer biomarkers such as EGFR, KRAS, and NRAS: PANAMutyperTM R EGFR T790M, PANAMutyperTM R EGFR L858R, PANAMutyperTM R KRAS series, and PANAMutyperTM R NRAS series. These products are research use only, and regulatory approval process is currently underway.

The company stated “Our KRAS and NRAS ctDNA kits can accurately classify 19 and 20 genotypes of mutation, respectively, and EGFR ctDNA kit can identify acquired drug-resistance mutation induced by targeted-therapy.” and “It’s not just about pioneering the new market of cancer diagnostics in blood tests. We anticipate this breakthrough to facilitate the development of new anticancer drugs that are aimed to target each mutation variant”.

Panagene Inc. is a leading PNA (Peptide Nucleic Acid) oligomer manufacturer, has developed various products based on PNA. In addition, the company has successfully commercialized diagnostic products in the domestic and competitive global markets. Panagene also specializes in mass production of PNA with strong patent portfolios and supplies products to more than 200 organizations in over 30 countries.

CONTACT

Panagene Inc.
MAX RYU
Deputy General Manager / Overseas
Marketing Dept
54, Techno 10-ro, Yuseong-gu
Daejeon, 305-510,
Korea
Tel: +82-42-861-9295
Fax: +82-42-861-9297
Email: max@panagene.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease